AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00605449
Drug: GSK376501
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00033644
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04652089
Drug: Simvastatin 20mg
RxNorm normalized name: SIMVASTATIN 20MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 20mg once a day for 7 days
Trial: NCT04652089
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once a day for 7 days
Trial: NCT00252356
Drug: SR58611A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00826943
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet daily x 7 days
Trial: NCT01348165
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder for oral solution
Trial: NCT02106260
Drug: CLS003
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00852436
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules in 75 mg,dosing increment from 150, 300, to 600mg/day at weekly intervals,administered orally one (or two, or four) capsule(s), twice daily. Fixed schedule of dosing increment from 150, 300, to 600mg/day at weekly intervals, until the highest tolerated dose has been reached. A single downward dose titration will be allowed depending on tolerability, after which the patient will remain on this dosage for the rest of the study.
Trial: NCT00000588
Drug: Chelation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After an initial 21 day balance study to demonstrate that a selected dose of PIH produced sufficient iron excretion, patients were begun on chronic therapy. PIH or placebo were given on days 4 to 9 and days 13 to 18 in a randomized, double-blind, cross-over design.
Trial: NCT02091882
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo-embedded IEM tablet.
Trial: NCT04340778
Drug: vaginal dinoprostone
RxNorm normalized name: dinoprostone Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vaginal dinoprostone 3 mg will be given 3 hours before copper IUD insertion plus inert placebo cream will be applied on the cervix at the time of IUD insertion
Trial: NCT04340778
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inert placebo Cream will be applied on the cervix at the time of IUD insertion plus vaginal placebo tablet will be given 3 hours prior to IUD insertion
Trial: NCT00645112
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral suspension 10 mg/kg QD on Day 1 then 5 mg/kg QD on Days 2-5 for a total of 5 days.
Trial: NCT00691314
Drug: Standard medical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Medical Management:including antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide)
Trial: NCT02154776
Drug: LEE011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 weeks on and 1 week off
Trial: NCT00004825
Drug: recombinant human insulin-like growth factor I
RxNorm normalized name: Recombinant human insulin-like growth factor I
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01877265
Drug: LY2605541
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02483975
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be provided as dry powder inhaler with 30 doses per device, each containing placebo as a dry white powder per blister, to be inhaled orally via ELLIPTA.
Trial: NCT01144286
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, single dose
Trial: NCT00442806
Drug: Injection of ADRC's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADRC's are injected
Trial: NCT01651377
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo pills. The placebo group is included to maintain the blind, rather than as a comparison group.
Trial: NCT03801252
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline
Trial: NCT00332007
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two tablets once daily
Trial: NCT03801252
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: prophylactic antibiotic
Trial: NCT02478632
Drug: Subjects do not receive study medication in this study 202094
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants do not receive study medication in this study 202094.
Trial: NCT02733432
Drug: CD101 Vaginal Gel (3%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD101 Vaginal Gel (3%) intravaginally applied topical gel on Days 1 and 2
Trial: NCT02733432
Drug: CD101 External gel (1%)
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD101 external gel (1%) applied topically twice daily over 72 hours as needed
Trial: NCT02733432
Drug: CD101 Vaginal Ointment (6%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD101 vaginal ointment (6%) intravaginally applied topical ointment on Day 1
Trial: NCT02733432
Drug: CD101 External ointment (1%)
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD101 external ointment (1%) applied topically twice daily over 72 hours as needed
Trial: NCT01986283
Drug: Capsule
RxNorm normalized name: CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken once
Trial: NCT03097120
Drug: 0.625 mg of conjugated equine estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet containing 0.625 mg of conjugated equine estrogen and a placebo tablet daily
Trial: NCT03097120
Drug: placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two placebo tablets daily
Trial: NCT03797729
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upon being diagnosed as ST Elevation Myocardial Infarction, if informed consent is obtained, patients start to receive normal saline intravenous drip in a dosage of 4ml/hour (patients weight\<50kg) or 6ml/hour (patients weight \> 50kg) lasting for 24 hours.
Trial: NCT02745522
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00755196
Drug: AN2728
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AN2728 Ointment, 5%, twice daily for 12 weeks
Trial: NCT00309972
Drug: Control arm (SEQ):
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four cycles of cisplatinum/vinorelbine given in a 21 day cycle followed by radical radiotherapy, 55 Gy in 20 once daily fractions in four weeks (2.75 Gy/day).
Trial: NCT03229057
Drug: OCP + Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
Trial: NCT00309972
Drug: Experimental arm (CON):
FDA approved: no
EMA approved: no
PMDA approved: no
Description: concurrent chemo-radiotherapy \[55 Gy in 20 daily fractions in 4 weeks (2.75 Gy/day) with cisplatinum given concurrently with fractions 1-4 and 16-19, and vinorelbine prior to fractions 1, 6, 15 and 20\] followed by two cycles of cisplatinum/vinorelbine.
Trial: NCT04277910
Drug: MT2004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT2004 oral capsules
Trial: NCT04277910
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsules
Trial: NCT01604850
Drug: SOF
RxNorm normalized name: Kasof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir (SOF) 400 mg tablet was administered orally once daily.
Trial: NCT01604850
Drug: Placebo to match SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match SOF was administered orally once daily.
Trial: NCT01604850
Drug: Placebo to match RBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match RBV was administered orally twice daily.
Trial: NCT03677141
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive cyclophosphamide via IV.
Trial: NCT03677141
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive doxorubicin via IV.
Trial: NCT02958514
Drug: Tobramycin and Dexamethasone Ophthalmic Ointment
RxNorm normalized name: Tobramycin and Dexamethasone Ophthalmic Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00019097
Drug: autologous tumor cell vaccine
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000308
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00548223
Drug: Dengzhan Shengmai capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, 0.18g, 2#, Bid\*1year
Trial: NCT00548223
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, 0.18g, 2#, Bid\*1year
Trial: NCT00002579
Drug: CMF regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002579
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002579
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02460159
Drug: EZ 10 mg/Atorva 20 mg FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02460159
Drug: EZ 10 mg/Atorva 10 mg FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03821883
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo qd
Trial: NCT01051232
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two subjects will receive the placebo under fasting condition.
Trial: NCT02268032
Drug: Another Androgenic Agent (VRaA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone 35 mg in vaginal ring
Trial: NCT04519437
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneous (SC) every 4 weeks (Q4W)
Trial: NCT00543309
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo bolus on CPB, then placebo infusion
Trial: NCT03006068
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally.
Trial: NCT03829839
Drug: Placebo nasalspray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo nasalspray contain identical ingredients except for the active agent itself.
Trial: NCT03829839
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo pill contain identical ingredients except for the active agent itself.
Trial: NCT00841919
Drug: lispro insulin
RxNorm normalized name: Lispro insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus (prandial) insulin as lispro insulin (choice between pens or vials will be made). The administration of bolus (prandial) insulin pen or syringe will be delivered concurrently with the food tray (the concept of insulin pen/syringe on the food tray) by the nursing staff that together with hospital food services identifies the food tray for the patients in the study group. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff.
Trial: NCT03191188
Drug: Levothyroxine Sodium
RxNorm normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thyroid hormone supplement
Trial: NCT03191188
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01480089
Drug: Atomized Intraperitoneal Saline (AIS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomized saline will be administered to the peritoneal cavity at the completion of surgery.
Trial: NCT03375593
Drug: Hydrocodone 5Mg/Acetaminophen 500Mg Tab
RxNorm normalized name: HYDROCODONE 5MG/ACETAMINOPHEN 500MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT03375593
Drug: Acetaminophen 500Mg Tab
RxNorm normalized name: ACETAMINOPHEN 500MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT03375593
Drug: Ibuprofen 600 mg tab
RxNorm normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: tablet
Trial: NCT01737671
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 mg into fourth ventricle of the brain via the Ommaya Reservoir for 4 days. Each patient will undergo three cycles with at least two weeks between each cycle.
Trial: NCT01737671
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg/square meter per dose administered every 6 hours by vein or mouth.
Trial: NCT00385710
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01998776
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Starch four times daily
Trial: NCT01669226
Drug: TCiv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5
Trial: NCT01135641
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00025896
Drug: recombinant human acid alpha-glucosidase (rhGAA)
RxNorm normalized name: alpha glucosidase
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00527800
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosed twice daily for 3 days, given in fixed dose tablets (20 mg artemether + 120 mg lumefantrine) according to weight-based guidelines
Trial: NCT01453075
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo twice daily
Trial: NCT01684969
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg iv , one dose
Trial: NCT03931408
Drug: Gentamicin Sulfate
RxNorm normalized name: Gentamicin Sulfate
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gentamicin will be compounded for immediate use in single-dose, disposable BD 50ml Luer-Lok tip syringes. The container closure system for the diluted gentamicin sulfate solution and saline solution will be sterile and processed with depyrogenation. The solution will be slowly infused into the bladder after drainage of urine is complete. While monitoring blood pressure, the solution will remain in the participant's bladder for a least 30 minutes (unless the participant is experiencing autonomic dysreflexia, and in that case, immediately drained) with the goal of attaining 2 hours.
Trial: NCT04500509
Drug: diclofenac potassium + dinoprostone
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will have of oral diclofenac potassium 60 minutes before the procedure plus one tablets of vaginal dinoprostone (6 mg) 6 hours prior to the procedure by the patient
Trial: NCT04500509
Drug: diclofenac potassium + placebo
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will have of oral diclofenac potassium 60 minutes before the procedure plus one tablets of vaginal placebo 6 hours prior to the procedure by the patient
Trial: NCT04289662
Drug: K-924 LD
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin 2 mg / Ezetimibe 10 mg tables
Trial: NCT04289662
Drug: K-924 HD
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin 4 mg / Ezetimibe 10 mg tables
Trial: NCT02246478
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Single-dose phase: 3steps (low dose, middle dose or high dose group), 2 patients/step, single oral administration after meals~* Multiple-dose phase: 3 steps (low dose, middle dose or high dose group), 2 patients/step (the same patients between single- and multiple-dose phases), repeated oral administration for 7 days, BID after meals
Trial: NCT01230580
Drug: Protease Inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch to a regimen comprising a single ritonavir-boosted Protease Inhibitor
Trial: NCT01230580
Drug: Standard-of-care Antiretroviral therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen should consist of 3 drugs: 2 nucleoside reverse transcriptase inhibitors with either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor
Trial: NCT03840057
Drug: Azithromycin Injection
RxNorm normalized name: azithromycin Injection
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin, a semi-synthetic macrolide antibiotic derived from erythromycin. The role of azithromycin as a prokinetic agent was first reported in a retrospective cohort study, which showed azithromycin to be equivalent to erythromycin in accelerating gastric emptying in patients with gastroparesis. The aim of this intervention arm is to evaluate the effectiveness of azithromycin as a prokinetic agent in the management of UGIB.
Trial: NCT02465567
Drug: BGF MDI 320/14.4/9.6 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budensonide, Glycopyrronium, and Formoterol Fumarate
Trial: NCT02465567
Drug: GFF MDI 14.4/9.6 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium, and Formoterol Fumarate
Trial: NCT02465567
Drug: BGF MDI 160/14.4/9.6 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budensonide, Glycopyrronium, and Formoterol Fumarate
Trial: NCT03879278
Drug: NPT189
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPT189 is a recombinant immunoglobulin Fc fusion of GAIM (GAIM-IgG1Fc) as a potential treatment for peripheral amyloidosis.
Trial: NCT03478930
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will not be receiving placebo in this OLE study. Participants who were randomized to the placebo arms for 24 weeks in studies GA39688/GA39855 and then enter this OLE study will receive omalizumab, but they will be placed in separate analysis cohorts.
Trial: NCT02224144
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sugar pill) 1 pill per day for 12 months
Trial: NCT03505008
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Route of Administration: Oral
Trial: NCT02940912
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cross-over with start with.Physiologic Serum in the 1st phase- in the 2nd phase of continuous treatment with Apokinon.
Trial: NCT02098967
Drug: RO6839921
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-escalating IV doses given on Days 1-5 of Cycle 1.
Trial: NCT02098967
Drug: RO6839921
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating IV doses of RO6839921 in solid tumor patients. Dose escalation will be calculated using the new Continual Reassessment Method (nCRM). RO6839921 will be given on Days 1-5 of 28-day cycles. Treatment will continue until disease progression, unacceptable toxicity or study discontinuation.
Trial: NCT02098967
Drug: RO6839921
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating IV doses of RO6839921 in AML patients. Escalation will follow an adapted rolling 6 design. Starting dose \</= dose inducing Grade 2 toxicity in patients with solid tumors. RO6839921 will be given on Days 1-5 of 28-day cycles. Treatment will continue until disease progression, unacceptable toxicity or study discontinuation.
Trial: NCT01164813
Drug: Nabumetone
RxNorm normalized name: Nabumetone
DrugBank: Nabumetone (DB00461)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
Trial: NCT02576249
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4cc of sterile normal saline (0.9%)
Trial: NCT01095926
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: blood sampling before, during and after doxorubicin administration
Trial: NCT03671044
Drug: Taxotere® (100 mg/m2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel Injection Concentrate; 20 mg/0.5 mL